After Hours Gainer
PMN Promis Neurosciences - Common Shares11.72-0.48-3.9%
After Hours:13.50+1.78 (+15.2%)
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease
Globe NewswireMon, 27-Jul 4:00 PM
